Skip to main content

Labcorp guidance

  • LH · NYSE
  • Healthcare
  • Health Care Services
  • S&P 500
$372.33−0.03%Close 17 Nov 2026 · Market value $30.00B

In its results release of 28 Oct 2026 (Q3 FY2026), Labcorp gave 3 forecasts in figures, among them revenue growth of +5.9% to +6.7% for FY2026. Over the last two years, results landed above the company's own last range 0 of 3 times, within it 3 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 28 Oct 2026

MeasurePeriodGuidanceAs stated
Revenue growthFY2026+5.9% to +6.7%Revenue growth range of 5.9% to 6.7%; up 50 basis points at the midpoint
EPS · AdjustedFY2026$18.30 to $18.70Adjusted EPS range of $18.30 to $18.70; up 18 cents at the midpoint
Free cash flowFY2026$1.24B to $1.36BFree Cash Flow $1,240 - $1,360

Source: the company's earnings release.

Guidance against results above 0 · within 3 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$14.61B to $14.79BGiven once—To come
Revenue growthFY2026+5.9% to +6.7%Raised twice—To come
EPS · AdjustedFY2026$18.30 to $18.70Raised twice—To come
Free cash flowFY2026$1.24B to $1.36BUnchanged—To come
Tax rate · AdjustedFY2026About 23%Given once—To come
RevenueFY2025$13.88B to $14.05BGiven once$13.95BWithin the range
EPS · AdjustedFY2025$16.15 to $16.50Raised once$16.44Within the range
EPS · AdjustedFY2024$14.30 to $14.70Given once$14.57Within the range

LH in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.